Synergistic Effect of YK-4-279 and Paclitaxel on A549 Cell Line

Proceedings

Gizir, Gamze¹  Alkhatib, Sara²  Kandemiş, Emine³  Bulut, Gülay⁴ 

[1] Authors to whom correspondence should be addressed.;Bioengineering Program, Graduate School of Natural and Applied Sciences, Bahçeşehir University, 34353 Istanbul, Turkey;Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Bahçeşehir University, 34353 Istanbul, Turkey;Presented at the 2nd International Cell Death Research Congress, Izmir, Turkey, 1–4 November 2018.

关键词: lung cancer;    ERG;    EMT;    YK-4-279;    paclitaxel;    synergistic effect;   

DOI  :  10.3390/proceedings2251588

学科分类：社会科学、人文和艺术（综合）

来源: mdpi

【 摘 要 】

Lung cancer, among all cancer types around the world, is listed as the major cause of death with high mortality rate. ERG transcription factor has an important role in the Epithelial Mesenchymal Transition (EMT), which is one of the most important mechanisms in lung cancer progression. It is known that a small molecule inhibitor YK-4-279 is a potential inhibitor of ERG expression in prostate cancer. In this study, the possible synergistic effect of YK-4-279 and another anticancer drug, Paclitaxel is analysed in non-small cell lung cancer (NSCLC) cell line, A549.

【 授权许可】

CC BY